{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:21:15Z","timestamp":1787754075069,"version":"build-2784847793"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Distal cholangiocarcinoma (dCCA) and pancreatic ductal adenocarcinoma (PDAC) share highly overlapping clinical presentations and radiological features, often leading to preoperative misdiagnosis. Therapeutic strategies for these malignancies differ substantially. While PDAC is commonly treated with gemcitabine plus nab-paclitaxel (AG regimen) or FOLFIRINOX as neoadjuvant or conversion therapy, first-line treatment for cholangiocarcinoma (CCA) typically consists of gemcitabine plus cisplatin (GC regimen), with or without immunotherapy. In recent years, increasing attention has been paid to immunotherapy-based combination strategies in biliary tract cancers, although their role in conversion therapy remains to be fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 70-year-old male presented with upper abdominal discomfort. Imaging findings and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) suggested moderately differentiated ductal adenocarcinoma. Based on the tumor location in the pancreatic uncinate process and associated vascular involvement, the lesion was initially considered borderline resectable PDAC. The patient received neoadjuvant therapy consisting of a programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) bispecific antibody (cadonilimab) combined with the AG regimen for seven cycles. Post-treatment imaging demonstrated marked tumor regression and reduced vascular involvement. The patient subsequently underwent pancreaticoduodenectomy, with partial resection and reconstruction of the superior mesenteric vein (SMV), as well as arterial divestment of the superior mesenteric artery (SMA), achieving R0 resection. However, postoperative pathological evaluation revealed that the tumor originated from the distal bile duct, confirming a final diagnosis of dCCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the limitations of EUS-FNA in accurately determining the primary tumor origin in periampullary and pancreatobiliary junction malignancies, while immunohistochemistry lacks sufficient specificity in this setting. Importantly, it demonstrates that the AG regimen combined with PD-1\/CTLA-4 bispecific immunotherapy, commonly used in PDAC, may exert significant antitumor activity in dCCA, providing a novel perspective for conversion therapy in biliary tract cancers. This report offers a preliminary real-world therapeutic insight from a single case, suggesting that dual immune checkpoint blockade combined with chemotherapy may enable conversion surgery in selected patients with CCA. Further studies are warranted to elucidate the underlying immunological mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1865799","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:22:42Z","timestamp":1787750562000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Distal cholangiocarcinoma mimicking pancreatic ductal adenocarcinoma successfully converted to resection following PD-1\/CTLA-4 bispecific immunotherapy (cadonilimab) combined with nab-paclitaxel\u2013based chemotherapy: a case report providing preliminary real-world insight"],"prefix":"10.3389","volume":"16","author":[{"given":"Yongzhao","family":"Li","sequence":"first","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyang","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyue","family":"Du","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengyuan","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mancai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlong","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gansu Provincial Second People\u2019s Hospital","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanteng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Second Hospital of Lanzhou University, Academician Workstation of The Second Hospital & Clinical Medical School, Lanzhou University","place":["Lanzhou, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1148\/rg.226025060","article-title":"Differential diagnosis of periampullary carcinomas at MR imaging","volume":"22","author":"Kim","year":"2002","journal-title":"RadioGraphics"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051454","article-title":"Extrahepatic distal cholangiocarcinoma vs. pancreatic ductal adenocarcinoma: Histology and molecular profiling for differential diagnosis and treatment","volume":"15","author":"Gkountakos","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2007.11.033","article-title":"Combined EUS with FNA and ERCP for the evaluation of patients with obstructive jaundice from presumed pancreatic Malignancy","volume":"68","author":"Ross","year":"2008","journal-title":"Gastrointestinal Endoscopy"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2023.04.018","article-title":"Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials","volume":"25","author":"Janssen","year":"2023","journal-title":"HPB"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-021-02120-w","article-title":"Pancreatic ductal adenocarcinoma and distal cholangiocarcinoma: A proposal of preoperative diagnostic score for differential diagnosis","volume":"19","author":"Muttillo","year":"2021","journal-title":"World J Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): A multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/j.ccell.2025.09.009","article-title":"Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial","volume":"43","author":"Bai","year":"2025","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): Patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000760","article-title":"Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations","volume":"82","author":"Wilbur","year":"2025","journal-title":"Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000529012","article-title":"A phase II study of nab-paclitaxel and gemcitabine as first-line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy (NACHO)","volume":"46","author":"Virchow","year":"2023","journal-title":"Oncol Res Treat"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34394","article-title":"A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT\u201001","volume":"128","author":"Sahai","year":"2022","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0286","article-title":"Nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in patients with metastatic biliary tract cancer: A randomized phase 2 study","volume":"30","author":"Markussen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241292264","article-title":"Second-line treatment of PD-1 and CTLA-4 blockade combined with liposomal irinotecan plus leucovorin and fluorouracil for advanced cholangiocarcinoma: Study protocol of a single-arm, prospective phase II trial","volume":"16","author":"Yang","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4143\/crt.2017.595","article-title":"Validation of the Eighth American Joint Committee on Cancer Staging System for distal bile duct carcinoma","volume":"51","author":"Jun","year":"2019","journal-title":"Cancer Res Treat"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1042493","article-title":"The consistencies and inconsistencies between distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: A systematic review and meta-analysis","volume":"12","author":"Lv","year":"2022","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1148\/rg.343125191","article-title":"Imaging features of benign and Malignant ampullary and periampullary lesions","volume":"34","author":"Nikolaidis","year":"2014","journal-title":"RadioGraphics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13197","DOI":"10.1038\/s41598-026-43859-0","article-title":"Diagnostic efficacy of endoscopic ultrasound-guided fine needle aspiration cytology in pancreatic lesions","volume":"16","author":"Mohanty","year":"2026","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2024.04.007","article-title":"Pancreas fine needle aspiration: Current and future impact on patient care","volume":"17","author":"Kwan","year":"2024","journal-title":"Surg Pathol Clinics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpdhp.2015.10.005","article-title":"Ancillary studies in EUS-FNA for solid pancreatic masses","volume":"21","author":"Jhala","year":"2015","journal-title":"Diagn Histopathology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13000-025-01638-x","article-title":"Revisiting the use of CK7 and CK20 immunohistochemical stains in pathological diagnoses","volume":"20","author":"Wang","year":"2025","journal-title":"Diagn Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jasc.2018.07.002","article-title":"Immunohistochemical staining for S100P, SMAD4, and IMP3 on cell block preparations is sensitive and highly specific for pancreatic ductal adenocarcinoma","volume":"7","author":"Sweeney","year":"2018","journal-title":"J Am Soc Cytopathology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14335","article-title":"Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: A systematic review and meta-analysis","volume":"8","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17857","article-title":"SMAD4 regulates the progression of cholangiocarcinoma by modulating the expression of STING1","volume":"27","author":"Shi","year":"2023","journal-title":"J Cell Mol Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"dmm050358","DOI":"10.1242\/dmm.050358","article-title":"Smad4 restricts injury-provoked biliary proliferation and carcinogenesis","volume":"17","author":"Alexander","year":"2024","journal-title":"Dis Model Mech"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.10.3500","article-title":"Synaptophysin: A marker protein for neuroendocrine cells and neoplasms","volume":"83","author":"Wiedenmann","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa164","article-title":"Combined use of INSM1 and synaptophysin is the most sensitive and specific panel to detect neuroendocrine neoplasms in the digestive tract","volume":"154","author":"Aldera","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(03)00268-5","article-title":"Expression of \u03b1-methylacyl-coa racemase (p504s) in various Malignant neoplasms and normal tissues: A study of 761 cases","volume":"34","author":"Jiang","year":"2003","journal-title":"Hum Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.humpath.2019.08.002","article-title":"The expression of gastrointestinal differentiation markers in extrahepatic cholangiocarcinoma: Clinicopathological significance based on tumor location","volume":"92","author":"Ishida","year":"2019","journal-title":"Hum Pathol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.5858\/2000-124-1196-eocaic","article-title":"Expression of cytokeratins 7 and 20 in carcinomas of the extrahepatic biliary tract, pancreas, and gallbladder","volume":"124","author":"Duval","year":"2000"},{"key":"B35","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/01.pas.0000149708.12335.6a","article-title":"Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: Application of CDX2, CK17, MUC1, and MUC2","volume":"29","author":"Chu","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01757.x","article-title":"Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma","volume":"102","author":"Hamada","year":"2011","journal-title":"Cancer Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2014-0072-ra","article-title":"Utility of immunohistochemistry in the pancreatobiliary tract","volume":"139","author":"Lin","year":"2015"},{"key":"B38","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/s41698-025-01139-6","article-title":"Profiling ADC targets in cholangiocarcinoma: Implications for therapeutic development","volume":"9","author":"Nakazawa","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1654425","article-title":"Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma: A retrospective real-world study","volume":"16","author":"Qin","year":"2025","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"103830","DOI":"10.1016\/j.labinv.2024.103830","article-title":"1587 Comparative immunohistochemical and molecular profiling of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and pancreatic ductal adenocarcinoma","volume":"105","author":"Beyersdorf","year":"2025","journal-title":"Lab Invest"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1321813","article-title":"The predictive value of PD-L1 expression in response to anti-PD-1\/PD-L1 therapy for biliary tract cancer: A systematic review and meta-analysis","volume":"15","author":"Yoon","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.09.014","article-title":"Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer","volume":"176","author":"Kim","year":"2022","journal-title":"Eur J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v16.i8.2689","article-title":"Management of distal cholangiocarcinoma with arterial involvement: Systematic review and case series on the role of neoadjuvant therapy","volume":"16","author":"Hall","year":"2024","journal-title":"World J Gastrointest Surg"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100354","article-title":"Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/17520363.2024.2385297","article-title":"Emerging biomarkers for immunotherapy response in biliary tract cancers: A comprehensive review of immune checkpoint inhibitor strategies","volume":"18","author":"Lou","year":"2024","journal-title":"biomark Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-022-01253-z","article-title":"Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses","volume":"15","author":"Xia","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32010024","article-title":"The immune landscape and its potential for immunotherapy in advanced biliary tract cancer","volume":"32","author":"Santoso","year":"2025","journal-title":"Curr Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975136","article-title":"The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review","volume":"12","author":"Cremen","year":"2022","journal-title":"Front Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1186\/s12885-025-15203-8","article-title":"Neoadjuvant chemotherapy followed by surgery versus upfront surgery for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"25","author":"Liu","year":"2025","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1865799\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:22:43Z","timestamp":1787750563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1865799\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":51,"alternative-id":["10.3389\/fonc.2026.1865799"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1865799","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1865799"}}